{"success":true,"data":{"pressRelease":{"id":"99431","rtpr_id":"nGNX5sTdCH","ticker":"COSM","exchange":"NASDAQ","all_tickers":["COSM"],"title":"Cosmos Health Advances Its Technology-Driven Transformation with an AI-Enabled Subscription Platform Across B2C and B2B Channels","author":"Globe Newswire","published_at":"2026-07-27T17:05:00.115Z","article_body":"* Digital subscription platform brings together the Company’s proprietary\nconsumer health products across consumer (B2C) and corporate (B2B) channels\n* Customers can begin through one of three paths: a free nutritionist\nconsultation, an AI-powered assistant, or building their own package\n* Corporate offering supports employee wellness programs and corporate gifting\nthrough multi-recipient management, tiered volume pricing, centralized\nbilling, and dedicated account management\n* Future platform enhancements are expected to include AI-driven\npersonalization and the potential integration of at-home testing and\ndiagnostic kits\n* Platform builds on the U.S. subscription launch of NOOR Collagen, which has\ndelivered an early repeat purchase rate above 60%\nCHICAGO, July 27, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc.\n(https://www.globenewswire.com/Tracker?data=TFkuaOBzNGE1l9RHB9pelpS4esXRnSgjGjGILWwrsQ-PprmhE3ZS760i3ale8l18O7V0FXNxDIve9pvX5GtYtoPUUzBwwpD1en_DGil5nfA=)\n(\"Cosmos Health\" or the “Company”) (NASDAQ:COSM)\n(https://www.globenewswire.com/Tracker?data=2GPJieeepamvLKrO3T7Vng1YcEG1zZqOYDwrcRrP3alvL2OUo9Pcuo76jAIEVKfiDhs8B4rRUIYmbDa8NM4b3UIKmEfwvOn1qhRl4yi-6Uo=),\na diversified, vertically integrated global healthcare group, today announced\nthat it is actively developing a flexible, technology-driven subscription\nplatform for its consumer health products, representing a significant step in\nthe Company’s broader technology-driven transformation.\n\nDesigned around customer choice, the platform will allow customers to begin\nwith a free consultation with a nutritionist, engage with an AI-powered\nassistant, or select products and build their own package. Based on each\ncustomer’s health and wellness goals, the platform will assemble a\npersonalized package consisting primarily of Cosmos Health’s proprietary\nproducts, supplemented where appropriate with third-party products to address\nbroader customer needs.\n\nThe platform is being designed to support multiple purchasing models,\nincluding consumer subscriptions (B2C) at the customer’s preferred\nfrequency; corporate subscriptions (B2B) for employee wellness programs and\ncorporate gifting, with multi-recipient management, tiered volume pricing,\ncentralized billing, and dedicated account management; and one-time or gift\npurchases that may convert into ongoing subscriptions.\n\nRecurring and one-time payments are expected to be processed through a secure,\nintegrated checkout, with invoicing available for corporate accounts.\n\nOver time, the Company intends to enhance the platform with AI-driven\npersonalization that refines recommendations based on customer data and\npreferences. Cosmos Health also plans to explore the integration of at-home\ntesting and diagnostic kits, which could allow subscriptions to be informed by\nindividualized health insights.\n\nThe platform builds on the subscription model\n(https://www.globenewswire.com/Tracker?data=4XWTgaWS1AWdkA2j7WHdVnVdq4Us4NPXBgdsMDI5fr3fAG14u2YWtKePyMEW_8GBhh70PjZ7s0nhMwCniUxMj7NeYYU514iLXOjAD-rUoeIjjkL8c8dSyMaRVn4Knnt8LkbiWRWExfzddt3wbN_6CSopdJk1XXXZ9D6AnqLh4tQsU9o2I8XLURjW6OkI7cPxFzSY9NKjRjpL99e769v65Q==)\nlaunched in the United States with NOOR Collagen, which has delivered\nencouraging early results, including a repeat purchase rate above 60%. The\nCompany intends to expand the platform into international markets as it\nadvances its strategy of building a scalable, technology-enabled,\nrecurring-revenue business.\n\nGreg Siokas, CEO of Cosmos Health, stated: \"We are building a subscription\nplatform designed to meet customers wherever they are—whether they are\nindividual consumers, corporate clients, or one-time buyers—and turn each\ninteraction into a lasting relationship. By combining personalized guidance\nwith technology, and over time AI-driven personalization and diagnostic\ninsights, we intend to deliver a differentiated consumer health experience\nwhile building the predictable, recurring revenue that creates long-term value\nfor our shareholders.”\n\nAbout Cosmos Health Inc.\nCosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a\ndiversified, vertically integrated global healthcare group. The Company owns a\nportfolio of proprietary pharmaceutical and nutraceutical brands, including\nSky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®.\nThrough its subsidiary Cana Laboratories S.A., licensed under European Good\nManufacturing Practices (GMP) and certified by the European Medicines Agency\n(EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides,\nand medical devices within the European Union. Cosmos Health also distributes\na broad line of pharmaceuticals and parapharmaceuticals, including branded\ngenerics and OTC medications, to retail pharmacies and wholesale distributors\nthrough its subsidiaries in Greece and the UK. Furthermore, the Company has\nestablished R&D partnerships targeting major health disorders such as obesity,\ndiabetes, and cancer, enhanced by artificial intelligence drug repurposing\ntechnologies, and focuses on the R&D of novel patented nutraceuticals,\nspecialized root extracts, proprietary complex generics, and innovative OTC\nproducts. Cosmos Health has also entered the telehealth space through the\nacquisition of ZipDoctor, Inc., based in Texas, USA. With a global\ndistribution platform, the Company is currently expanding throughout Europe,\nAsia, and North America, and has offices and distribution centers in\nThessaloniki and Athens, Greece, and in Harlow, UK. More information is\navailable at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co,\nwww.cloudscreen.gr, as well as LinkedIn\n(https://www.globenewswire.com/Tracker?data=1Ufd4ddX6Ru_mQbqUgyD36Bq99nQ1McqzdJcZDUYanaKL8UKBlLbADwLGrbcToOO4xYKg8lHCi_ojqMjWwMoB9ck_hO4N--j0dfDDsuu__hSAANATe8kh5Oah5mHbIFx)\nand X\n(https://www.globenewswire.com/Tracker?data=iw_k0C43NIz54dJ12vg0LbCblQuOvEYBZTIXId_uc-OiB7RUdimAxTef5Yvl5cBAdSgpyDKzaH8z71BXIPTEqWZMa3TCHzzlc-WnmzBhBeM=).\n\nForward-Looking Statements\nWith the exception of the historical information contained in this news\nrelease, the matters described herein may contain forward-looking statements\nwithin the meaning of Section 27A of the Securities Act of 1933, as amended,\nand Section 21E of the Securities Exchange Act of 1934, as amended. Words such\nas “believes,” “expects,” “anticipates,” “intends,”\n“projects,” “estimates,” “plans,” and similar expressions, or\nfuture or conditional verbs such as “will,” “should,” “would,”\n“may,” and “could,” generally identify forward-looking statements,\nalthough not all forward-looking statements contain these words. These\nstatements involve risks and uncertainties that may individually or materially\naffect the matters discussed herein for a variety of reasons outside the\nCompany’s control, including, but not limited to: the Company’s ability to\nraise sufficient financing to implement its business plan; the effectiveness\nof its digital asset strategies, including accumulation and yield-generating\nactivities; the impact of the war in Ukraine and ongoing conflicts in the\nMiddle East and other regions on the Company’s business, operations, and the\neconomy in general; the Company’s ability to successfully develop and\ncommercialize its proprietary products and technologies; changes in interest\nrates; changes in foreign currency exchange rates, commodity or other price\ninflation and deflation; our ability to issue debt on terms and at rates\nacceptable to us; the impact and expected outcome of investigations,\ninquiries, claims, and litigation; the challenges of operating in\ninternational markets; the adequacy of insurance coverage; the effect of\naccounting charges and of adopting certain accounting standards; the impact of\nlegal and regulatory changes, including changes to tax laws and regulations;\nguidance for fiscal 2026 and beyond and financial outlook. Forward-looking\nstatements are based on currently available information and our current\nassumptions, expectations and projections about future events. You should not\nrely on our forward-looking statements. These statements are not guarantees of\nfuture performance and are subject to future events, risks and uncertainties\n– many of which are beyond our control, dependent on the actions of third\nparties, or currently unknown to us – as well as potentially inaccurate\nassumptions that could cause actual results to differ materially from our\nhistorical experience and our expectations and projections. These risks and\nuncertainties include, but are not limited to, those described from time to\ntime in our periodic reports filed with the SEC and available at the SEC’s\nwebsite (www.sec.gov). There also may be other factors that we cannot\nanticipate or that are not described herein, generally because we do not\ncurrently perceive them to be material. Such factors could cause results to\ndiffer materially from our expectations. Forward-looking statements speak only\nas of the date they are made, and we do not undertake to update these\nstatements other than as required by law. You are advised, however, to review\nany further disclosures we make on related subjects in our filings with the\nSecurities and Exchange Commission and in our other public statements.\n\nInvestor Relations Contact:\nBDG Communications\ncosm@bdgcommunications.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/29681d62-58aa-4ccf-bad9-cb7ce8ae66e4)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX5sTdCH","title":"Cosmos Health Advances Its Technology-Driven Transformation with an AI-Enabled Subscription Platform Across B2C and B2B Channels","author":"Globe Newswire","ticker":"COSM","created":"2026-07-27T17:05:00.115Z","tickers":["COSM"],"exchange":"NASDAQ","article_body":"* Digital subscription platform brings together the Company’s proprietary\nconsumer health products across consumer (B2C) and corporate (B2B) channels\n* Customers can begin through one of three paths: a free nutritionist\nconsultation, an AI-powered assistant, or building their own package\n* Corporate offering supports employee wellness programs and corporate gifting\nthrough multi-recipient management, tiered volume pricing, centralized\nbilling, and dedicated account management\n* Future platform enhancements are expected to include AI-driven\npersonalization and the potential integration of at-home testing and\ndiagnostic kits\n* Platform builds on the U.S. subscription launch of NOOR Collagen, which has\ndelivered an early repeat purchase rate above 60%\nCHICAGO, July 27, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc.\n(https://www.globenewswire.com/Tracker?data=TFkuaOBzNGE1l9RHB9pelpS4esXRnSgjGjGILWwrsQ-PprmhE3ZS760i3ale8l18O7V0FXNxDIve9pvX5GtYtoPUUzBwwpD1en_DGil5nfA=)\n(\"Cosmos Health\" or the “Company”) (NASDAQ:COSM)\n(https://www.globenewswire.com/Tracker?data=2GPJieeepamvLKrO3T7Vng1YcEG1zZqOYDwrcRrP3alvL2OUo9Pcuo76jAIEVKfiDhs8B4rRUIYmbDa8NM4b3UIKmEfwvOn1qhRl4yi-6Uo=),\na diversified, vertically integrated global healthcare group, today announced\nthat it is actively developing a flexible, technology-driven subscription\nplatform for its consumer health products, representing a significant step in\nthe Company’s broader technology-driven transformation.\n\nDesigned around customer choice, the platform will allow customers to begin\nwith a free consultation with a nutritionist, engage with an AI-powered\nassistant, or select products and build their own package. Based on each\ncustomer’s health and wellness goals, the platform will assemble a\npersonalized package consisting primarily of Cosmos Health’s proprietary\nproducts, supplemented where appropriate with third-party products to address\nbroader customer needs.\n\nThe platform is being designed to support multiple purchasing models,\nincluding consumer subscriptions (B2C) at the customer’s preferred\nfrequency; corporate subscriptions (B2B) for employee wellness programs and\ncorporate gifting, with multi-recipient management, tiered volume pricing,\ncentralized billing, and dedicated account management; and one-time or gift\npurchases that may convert into ongoing subscriptions.\n\nRecurring and one-time payments are expected to be processed through a secure,\nintegrated checkout, with invoicing available for corporate accounts.\n\nOver time, the Company intends to enhance the platform with AI-driven\npersonalization that refines recommendations based on customer data and\npreferences. Cosmos Health also plans to explore the integration of at-home\ntesting and diagnostic kits, which could allow subscriptions to be informed by\nindividualized health insights.\n\nThe platform builds on the subscription model\n(https://www.globenewswire.com/Tracker?data=4XWTgaWS1AWdkA2j7WHdVnVdq4Us4NPXBgdsMDI5fr3fAG14u2YWtKePyMEW_8GBhh70PjZ7s0nhMwCniUxMj7NeYYU514iLXOjAD-rUoeIjjkL8c8dSyMaRVn4Knnt8LkbiWRWExfzddt3wbN_6CSopdJk1XXXZ9D6AnqLh4tQsU9o2I8XLURjW6OkI7cPxFzSY9NKjRjpL99e769v65Q==)\nlaunched in the United States with NOOR Collagen, which has delivered\nencouraging early results, including a repeat purchase rate above 60%. The\nCompany intends to expand the platform into international markets as it\nadvances its strategy of building a scalable, technology-enabled,\nrecurring-revenue business.\n\nGreg Siokas, CEO of Cosmos Health, stated: \"We are building a subscription\nplatform designed to meet customers wherever they are—whether they are\nindividual consumers, corporate clients, or one-time buyers—and turn each\ninteraction into a lasting relationship. By combining personalized guidance\nwith technology, and over time AI-driven personalization and diagnostic\ninsights, we intend to deliver a differentiated consumer health experience\nwhile building the predictable, recurring revenue that creates long-term value\nfor our shareholders.”\n\nAbout Cosmos Health Inc.\nCosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a\ndiversified, vertically integrated global healthcare group. The Company owns a\nportfolio of proprietary pharmaceutical and nutraceutical brands, including\nSky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®.\nThrough its subsidiary Cana Laboratories S.A., licensed under European Good\nManufacturing Practices (GMP) and certified by the European Medicines Agency\n(EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides,\nand medical devices within the European Union. Cosmos Health also distributes\na broad line of pharmaceuticals and parapharmaceuticals, including branded\ngenerics and OTC medications, to retail pharmacies and wholesale distributors\nthrough its subsidiaries in Greece and the UK. Furthermore, the Company has\nestablished R&D partnerships targeting major health disorders such as obesity,\ndiabetes, and cancer, enhanced by artificial intelligence drug repurposing\ntechnologies, and focuses on the R&D of novel patented nutraceuticals,\nspecialized root extracts, proprietary complex generics, and innovative OTC\nproducts. Cosmos Health has also entered the telehealth space through the\nacquisition of ZipDoctor, Inc., based in Texas, USA. With a global\ndistribution platform, the Company is currently expanding throughout Europe,\nAsia, and North America, and has offices and distribution centers in\nThessaloniki and Athens, Greece, and in Harlow, UK. More information is\navailable at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co,\nwww.cloudscreen.gr, as well as LinkedIn\n(https://www.globenewswire.com/Tracker?data=1Ufd4ddX6Ru_mQbqUgyD36Bq99nQ1McqzdJcZDUYanaKL8UKBlLbADwLGrbcToOO4xYKg8lHCi_ojqMjWwMoB9ck_hO4N--j0dfDDsuu__hSAANATe8kh5Oah5mHbIFx)\nand X\n(https://www.globenewswire.com/Tracker?data=iw_k0C43NIz54dJ12vg0LbCblQuOvEYBZTIXId_uc-OiB7RUdimAxTef5Yvl5cBAdSgpyDKzaH8z71BXIPTEqWZMa3TCHzzlc-WnmzBhBeM=).\n\nForward-Looking Statements\nWith the exception of the historical information contained in this news\nrelease, the matters described herein may contain forward-looking statements\nwithin the meaning of Section 27A of the Securities Act of 1933, as amended,\nand Section 21E of the Securities Exchange Act of 1934, as amended. Words such\nas “believes,” “expects,” “anticipates,” “intends,”\n“projects,” “estimates,” “plans,” and similar expressions, or\nfuture or conditional verbs such as “will,” “should,” “would,”\n“may,” and “could,” generally identify forward-looking statements,\nalthough not all forward-looking statements contain these words. These\nstatements involve risks and uncertainties that may individually or materially\naffect the matters discussed herein for a variety of reasons outside the\nCompany’s control, including, but not limited to: the Company’s ability to\nraise sufficient financing to implement its business plan; the effectiveness\nof its digital asset strategies, including accumulation and yield-generating\nactivities; the impact of the war in Ukraine and ongoing conflicts in the\nMiddle East and other regions on the Company’s business, operations, and the\neconomy in general; the Company’s ability to successfully develop and\ncommercialize its proprietary products and technologies; changes in interest\nrates; changes in foreign currency exchange rates, commodity or other price\ninflation and deflation; our ability to issue debt on terms and at rates\nacceptable to us; the impact and expected outcome of investigations,\ninquiries, claims, and litigation; the challenges of operating in\ninternational markets; the adequacy of insurance coverage; the effect of\naccounting charges and of adopting certain accounting standards; the impact of\nlegal and regulatory changes, including changes to tax laws and regulations;\nguidance for fiscal 2026 and beyond and financial outlook. Forward-looking\nstatements are based on currently available information and our current\nassumptions, expectations and projections about future events. You should not\nrely on our forward-looking statements. These statements are not guarantees of\nfuture performance and are subject to future events, risks and uncertainties\n– many of which are beyond our control, dependent on the actions of third\nparties, or currently unknown to us – as well as potentially inaccurate\nassumptions that could cause actual results to differ materially from our\nhistorical experience and our expectations and projections. These risks and\nuncertainties include, but are not limited to, those described from time to\ntime in our periodic reports filed with the SEC and available at the SEC’s\nwebsite (www.sec.gov). There also may be other factors that we cannot\nanticipate or that are not described herein, generally because we do not\ncurrently perceive them to be material. Such factors could cause results to\ndiffer materially from our expectations. Forward-looking statements speak only\nas of the date they are made, and we do not undertake to update these\nstatements other than as required by law. You are advised, however, to review\nany further disclosures we make on related subjects in our filings with the\nSecurities and Exchange Commission and in our other public statements.\n\nInvestor Relations Contact:\nBDG Communications\ncosm@bdgcommunications.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/29681d62-58aa-4ccf-bad9-cb7ce8ae66e4)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-07-27T17:05:00.155241323Z","server_sent_at_ms":1785171900155},"received_at":"2026-07-27T17:05:00.207Z","source_url":"https://www.globenewswire.com/news-release/2026/07/27/3333785/0/en/cosmos-health-advances-its-technology-driven-transformation-with-an-ai-enabled-subscription-platform-across-b2c-and-b2b-channels.html"},"analysis":{"id":"88473","press_release_id":"99431","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"product_launch","narrative":"Cosmos Health is developing a flexible, technology-driven subscription platform for its consumer health products, supporting both B2C and B2B channels.\n\nThe platform offers multiple entry paths including nutritionist consultations, an AI-powered assistant, and self-customized packages, with future enhancements planned for AI-driven personalization and diagnostic kit integration.\n\nThis initiative builds on the successful U.S. subscription launch of NOOR Collagen, which has achieved an early repeat purchase rate above 60%.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Cosmos Health launches AI-enabled subscription platform to boost recurring revenue."},"keyFigures":{"customDimensions":{"repeat_purchase_rate":"60%"}},"quotedText":"We are building a subscription platform designed to meet customers wherever they are—whether they are individual consumers, corporate clients, or one-time buyers—and turn each interaction into a lasting relationship.","namedEntities":{"people":[{"name":"Greg Siokas","role":"CEO"}],"products":["NOOR Collagen","Sky Premium Life®","Mediterranation®","bio-bebe®","C-Sept®","C-Scrub®"],"companies":[{"name":"Cosmos Health Inc.","ticker":"COSM"},{"name":"Cana Laboratories S.A.","relationship":"subsidiary"},{"name":"ZipDoctor, Inc.","relationship":"subsidiary"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"The announcement of a technology-driven subscription platform is a positive strategic development, particularly given the strong early repeat purchase rate of over 60% for NOOR Collagen. However, the platform is still in development or early stages, so the immediate material impact is moderate."},"tickerRelevance":{"others":[],"primary":"COSM"},"globalImportance":25,"audienceRelevance":20,"eventTypeSecondary":["operations_update"],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"product-launch/strategic-initiative","sectorWeight":"health-care"}},"event_type":"product_launch","event_type_secondary":["operations_update"],"sentiment":"bullish","material_impact_score":2,"narrative":"Cosmos Health is developing a flexible, technology-driven subscription platform for its consumer health products, supporting both B2C and B2B channels.\n\nThe platform offers multiple entry paths including nutritionist consultations, an AI-powered assistant, and self-customized packages, with future enhancements planned for AI-driven personalization and diagnostic kit integration.\n\nThis initiative builds on the successful U.S. subscription launch of NOOR Collagen, which has achieved an early repeat purchase rate above 60%.","key_figures":{"customDimensions":{"repeat_purchase_rate":"60%"}},"named_entities":{"people":[{"name":"Greg Siokas","role":"CEO"}],"products":["NOOR Collagen","Sky Premium Life®","Mediterranation®","bio-bebe®","C-Sept®","C-Scrub®"],"companies":[{"name":"Cosmos Health Inc.","ticker":"COSM"},{"name":"Cana Laboratories S.A.","relationship":"subsidiary"},{"name":"ZipDoctor, Inc.","relationship":"subsidiary"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-07-27T19:27:14.031Z","global_importance":25,"audience_relevance":20,"importance_components":{"tickerTier":"small-cap","eventGravity":"product-launch/strategic-initiative","sectorWeight":"health-care"}},"durationMs":254894,"modelName":"glm-4.7"}}